Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.13 USD
Change Today +0.05 / 2.40%
Volume 797.4K
IMMU On Other Exchanges
As of 12:06 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

immunomedics inc (IMMU) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - $5.48
52 Week Low
07/28/15 - $1.83
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOMEDICS INC (IMMU)

immunomedics inc (IMMU) Related Bloomberg News

View More Bloomberg News

immunomedics inc (IMMU) Related Businessweek News

No Related Businessweek News Found

immunomedics inc (IMMU) Details

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer. The company’s antibody-drug conjugate (ADC) products comprise IMMU-132, an ADC that contains SN-38, which is in Phase 2 clinical development focusing on triple-negative breast cancer and colorectal cancer; and IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II clinical development for the treatment of metastatic colorectal cancer. Its early-stage products include Veltuzumab, a humanized monoclonal antibody, which is in Phase 2 study; Milatuzumab, an anti-CD74 antibody for the treatment of graft-versus-host disease that has completed initial Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL, which is in Phase 1/2 clinical trial; Milatuzumab-Doxorubicin, a clinically-evaluated agent that is in Phase 1 dose-escalation trial; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone in patients. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has strategic partnership with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

120 Employees
Last Reported Date: 08/25/14
Founded in 1982

immunomedics inc (IMMU) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $618.9K
Founder, Chairman of The Board and Director o...
Total Annual Compensation: $584.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $235.5K
Compensation as of Fiscal Year 2014.

immunomedics inc (IMMU) Key Developments

Immunomedics, Inc. Announces Encouraging Results from Colorectal Cancer Analysis

Immunomedics Inc. has announced an interim analysis of a mid-stage clinical study showed that its antibody-drug conjugate, or ADC, labetuzumab govitecan, produced encouraging survival results in patients previously treated with at least one prior irinotecan-containing regimen for their metastatic colorectal cancer, or mCRC. For the 33 patients who received the ADC at the 8 or 10 mg/kg dose levels, the interim median progression-free survival (PFS), a measure of the length of time the patient is living without their disease getting worse from the beginning of their labetuzumab govitecan treatments, was 4.4 months, with 22% of these patients still benefiting from their cancer not progressing. In terms of treatment response, in 32 patients with at least one evaluation following treatments with labetuzumab govitecan at the 8 or 10 mg/kg level, 1 patient had a partial response and 24 patients reported stable disease as their best response, to give a combined disease control rate of 78%. Treatment response was evaluated in accordance with the rules set by the Response Evaluation Criteria In Solid Tumors (RECIST 1.1) using computed tomography as the imaging tool for tumor size measurements. Labetuzumab govitecan was well tolerated by patients. At the optimal once-a-week doses of 8 and 10 mg/kg, grades 3 and 4 adverse events with occurrence of 5% or more included neutropenia (5% for both dose levels), and mild diarrhea (5% in the 8 mg/kg group only). Despite repeated dosing, no antibody against labetuzumab or its SN-38 conjugate was detected in blood samples from 74 patients over a 16-month period. At the time of analysis, 87 patients have been enrolled to receive the ADC in the first 2 weeks of a 21-day cycle. In addition to the 8 and 10 mg/kg once-weekly dose, other dosing levels and schedule evaluated included 4, 6, 9, and 12 mg/kg, each at a frequency of twice a week. The company created labetuzumab govitecan by conjugating the moderately-toxic drug, SN-38, site-specifically and at a high ratio of drug to labetuzumab, a humanized antibody that recognizes the carcinoembryonic antigen (CEA; CEACAM5 or CD66e) expressed in many solid cancers, including more than 90% of colorectal cancer. SN-38 is the active metabolite of irinotecan (Camptosar), which is used to treat certain solid cancers, particularly metastatic colorectal cancers, as a part of combination therapies, so its pharmacology and properties are well-known.

Immunomedics, Inc. Reports Complete Responses in Patients with Metastatic Triple-Negative Breast Cancer After Sacituzumab Govitecan Treatment

Immunomedics Inc. announced that among 49 patients with metastatic triple-negative breast cancer (TNBC) evaluated for response to treatments with sacituzumab govitecan in a mid-stage clinical study, 31%, or 15 patients, showed a reduction in tumor size of 30% or more. They include 2 patients with complete response. Response assessments were based on the rules set by the Response Evaluation Criteria In Solid Tumors (RECIST 1.1). Adding the 22 patients with responses between less than 30% tumor shrinkage and less than 20% tumor increase, the disease control rate was 76%. Sacituzumab govitecan also produced significant duration of response in these responding patients. Measured as the time it takes from the beginning of sacituzumab govitecan treatments to when the cancer progresses, the median progression-free survival (PFS) for the 48 patients who received the optimal doses of 8 or 10 mg/kg was 6.0 months. Importantly, 63% of patients (22 of 35) had a time-to-progression longer than their last therapy, notwithstanding disease progression has not yet happened in 56% of patients at the time of analysis. A total of 58 patients with relapsed or refractory metastatic TNBC have been enrolled into the multicenter study to receive sacituzumab govitecan once a week for 2 weeks in 21-day cycles. Despite repeated dosing, sacituzumab govitecan was well tolerated by patients. At the optimal doses of 8 and 10 mg/kg, transient neutropenia was the major Grade 3 or 4 adverse events with 26% occurrence. Grade 3 diarrhea was minimal, reported by only 2% of patients.

Immunomedics Inc. Announces Five Presentations at 2015 ASCO Focusing on Antibody-Drug Conjugate Programs

Immunomedics Inc. announced that two of its five abstracts submitted to the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) have been accepted as oral presentations. The two oral presentations will be on the Company's second generation antibody-drug conjugate (ADC) programs for solid cancer therapy. Leading that program is sacituzumab govitecan, an anti-TROP-2 antibody conjugated with SN-38, an active drug from irinotecan. Irinotecan is approved for the treatment of patients with colorectal cancer. Results from a Phase 2 study of sacituzumab govitecan in patients with advanced lung cancer will be updated in one of the 2 oral presentations. In addition to this oral presentation, results with sacituzumab govitecan in patients with late-stage triple-negative breast and gastrointestinal cancers will be reported in a Poster Discussion and a Poster Sessions, respectively. Also presented, in the same Oral Abstract Session as sacituzumab govitecan, will be initial results from a Phase 2 study of labetuzumab govitecan, another SN-38-containing ADC, for patients with metastatic colorectal cancer. The fifth presentation will feature a pilot study on TF2, a bispecific antibody, for pretargeted imaging of breast cancer in a Poster Session.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMU:US $2.13 USD +0.05

IMMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMU.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.1x
Price/Book 35.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at